-
1 Comment
Helius Medical Technologies, Inc is currently in a long term uptrend where the price is trading 9.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.7.
Helius Medical Technologies, Inc's total revenue rose by 25.7% to $191K since the same quarter in the previous year.
Its net income has increased by 52.4% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 52.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Helius Medical Technologies, Inc gets an overall score of 5/5.
| Exchange | TO |
|---|---|
| CurrencyCode | CAD |
| ISIN | US42328V6039 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 43M |
|---|---|
| Beta | 0.83 |
| PE Ratio | None |
| Target Price | 2.12 |
| Dividend Yield | 0.0% |
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HSM.TO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
